DE69712578T2 - Verwendung mindestens eines in 6-Stellung substituierten Pyrimidin-3-oxids zur Stimulierung von Tyrosinase - Google Patents

Verwendung mindestens eines in 6-Stellung substituierten Pyrimidin-3-oxids zur Stimulierung von Tyrosinase

Info

Publication number
DE69712578T2
DE69712578T2 DE69712578T DE69712578T DE69712578T2 DE 69712578 T2 DE69712578 T2 DE 69712578T2 DE 69712578 T DE69712578 T DE 69712578T DE 69712578 T DE69712578 T DE 69712578T DE 69712578 T2 DE69712578 T2 DE 69712578T2
Authority
DE
Germany
Prior art keywords
pyrimidine
oxide substituted
tyrosinase
stimulating
stimulating tyrosinase
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE69712578T
Other languages
English (en)
Other versions
DE69712578D1 (de
Inventor
Francis Pruche
Catherine Gerst
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
LOreal SA
Original Assignee
LOreal SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by LOreal SA filed Critical LOreal SA
Application granted granted Critical
Publication of DE69712578D1 publication Critical patent/DE69712578D1/de
Publication of DE69712578T2 publication Critical patent/DE69712578T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A61Q19/04—Preparations for care of the skin for chemically tanning the skin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
    • A61K8/494—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with more than one nitrogen as the only hetero atom
    • A61K8/4953—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with more than one nitrogen as the only hetero atom containing pyrimidine ring derivatives, e.g. minoxidil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q5/00—Preparations for care of the hair
    • A61Q5/06—Preparations for styling the hair, e.g. by temporary shaping or colouring
    • A61Q5/065—Preparations for temporary colouring the hair, e.g. direct dyes

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Birds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Cosmetics (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
DE69712578T 1996-09-17 1997-08-21 Verwendung mindestens eines in 6-Stellung substituierten Pyrimidin-3-oxids zur Stimulierung von Tyrosinase Expired - Fee Related DE69712578T2 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR9611316A FR2753378B1 (fr) 1996-09-17 1996-09-17 Utilisation dans une composition en tant que stimulateur de tyrosinase d'au moins un derive de pyrimidine 3-oxyde, substitue en 6

Publications (2)

Publication Number Publication Date
DE69712578D1 DE69712578D1 (de) 2002-06-20
DE69712578T2 true DE69712578T2 (de) 2003-03-13

Family

ID=9495805

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69712578T Expired - Fee Related DE69712578T2 (de) 1996-09-17 1997-08-21 Verwendung mindestens eines in 6-Stellung substituierten Pyrimidin-3-oxids zur Stimulierung von Tyrosinase

Country Status (12)

Country Link
US (2) US6380263B1 (de)
EP (1) EP0829260B1 (de)
JP (1) JP2999163B2 (de)
AR (1) AR009763A1 (de)
AT (1) ATE217518T1 (de)
AU (1) AU700465B2 (de)
BR (1) BR9702882A (de)
CA (1) CA2214426A1 (de)
DE (1) DE69712578T2 (de)
ES (1) ES2176639T3 (de)
FR (1) FR2753378B1 (de)
ZA (1) ZA977426B (de)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4610040B2 (ja) 2000-04-04 2011-01-12 東レ・ダウコーニング株式会社 育毛剤用添加剤及び育毛剤組成物
DE10150412A1 (de) * 2001-10-11 2003-04-17 Beiersdorf Ag Verwendung einer oder mehreren Substanzen, gewählt aus der Gruppe der Pyrimidine und Purine in kosmetischen Zubereitungen zur Bräunung der Haut
DE10150445A1 (de) * 2001-10-12 2003-04-17 Beiersdorf Ag Verwendung einer oder mehreren Substanzen, gewählt aus der Gruppe der Pyrimidine und Purine in kosmetischen Zubereitungen zur Haarfärbung
SE0104421D0 (sv) * 2001-12-21 2001-12-21 Ponsus Pharma Ab New composition
US7585514B2 (en) * 2002-06-11 2009-09-08 L'oreal Administration of agents mimicking DOPAchrome tautomerase (TRP-2) activity for protecting hair follicle melanocytes
GT200500284A (es) * 2004-10-15 2006-03-27 Aventis Pharma Inc Pirimidinas como antagonistas del receptor de prostaglandina d2
FR2883177B1 (fr) * 2005-03-15 2008-01-25 Oreal Utilisation d'agrnets tels que des donneurs ou liberateurs non polymeriques de monoxyde d'azote pour repulper et/ou colorer naturellement les levres
WO2006097348A1 (en) * 2005-03-15 2006-09-21 L'oreal Use of agents such as nonpolymeric nitric oxide donors for making the lips full again and/or colouring the lips
FR2883170A1 (fr) * 2005-03-15 2006-09-22 Oreal Utilisation d'agents tels que des donneurs ou liberateurs non polymeriques de monoxyde d'azote pour colorer naturellement la peau
FR2883171B1 (fr) * 2005-03-15 2007-05-11 Oreal Utilisation d'agents tels que des donneurs ou liberateurs non polymeriques de monoxyde d'azote pour diminuer les poches et/ou les cernes perioculaires
US20060156481A1 (en) * 2005-03-22 2006-07-20 The Procter & Gamble Company Keratin dyeing compounds, keratin dyeing compositions containing them, and use thereof
FR2951938B1 (fr) 2009-10-30 2012-01-06 Oreal Utilisation d'un extrait de punica granatum pour lutter contre la canitie
US11786447B2 (en) 2016-06-30 2023-10-17 The Procter & Gamble Company Conditioner composition comprising a chelant
US20180000705A1 (en) 2016-06-30 2018-01-04 The Procter & Gamble Company Shampoo Compositions Comprising a Chelant
US20180000715A1 (en) 2016-06-30 2018-01-04 The Procter & Gamble Company Hair Care Compositions For Calcium Chelation
US20180000706A1 (en) 2016-06-30 2018-01-04 The Procter & Gamble Company Conditioner Composition Comprising a Chelant
US11246816B2 (en) 2016-06-30 2022-02-15 The Procter And Gamble Company Shampoo compositions comprising a chelant

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3382248A (en) * 1965-11-01 1968-05-07 Upjohn Co 6-amino-4, 5-di(substituted amino)-1, 2-dihydro-1-hydroxy-2-iminopyrimidines
US3644364A (en) * 1970-03-31 1972-02-22 Upjohn Co Compounds and process
JPS61227518A (ja) * 1985-04-01 1986-10-09 Takeo Kinji 白髪防止化粧料
FR2677884B1 (fr) * 1991-06-20 1993-07-09 Oreal Composition pour freiner la chute des cheveux a base de pyrimidines n-oxyde trisubstitues ou leurs derives sulfoconjugues, nouveaux composes pyrimidines n-oxyde ou leurs derives sulfoconjugues.
FR2732597B1 (fr) * 1995-04-05 1997-05-16 Oreal Utilisation dans une composition en tant qu'activateur et/ou stabilisateur de cyclooxygenase d'au moins un derive de pyrimidine substitue en 6

Also Published As

Publication number Publication date
BR9702882A (pt) 1998-12-22
JPH10101519A (ja) 1998-04-21
AU700465B2 (en) 1999-01-07
JP2999163B2 (ja) 2000-01-17
ZA977426B (en) 1998-03-02
AU3415697A (en) 1998-03-19
US6380263B1 (en) 2002-04-30
FR2753378B1 (fr) 1998-11-20
CA2214426A1 (fr) 1998-03-17
EP0829260A1 (de) 1998-03-18
FR2753378A1 (fr) 1998-03-20
DE69712578D1 (de) 2002-06-20
AR009763A1 (es) 2000-05-03
US20020103216A1 (en) 2002-08-01
ATE217518T1 (de) 2002-06-15
ES2176639T3 (es) 2002-12-01
EP0829260B1 (de) 2002-05-15

Similar Documents

Publication Publication Date Title
DE69712578D1 (de) Verwendung mindestens eines in 6-Stellung substituierten Pyrimidin-3-oxids zur Stimulierung von Tyrosinase
DE69941566D1 (de) N-acetylhomotaurinate zur verwendung in der behandlung von hyperkinesie
DE69700109D1 (de) Verwendung eines Extrakts mindestens einer Iridacea bei der Behandlung von Falten
ATA227794A (de) Beschlag zur höhenverstellung von schubladen
DE69713295D1 (de) Azabicyclishe carbaniumsaureester zur therapeutsichen verwendung
DE59007513D1 (de) Anordnung zur Gewebestimulation.
ATE218355T1 (de) Verwendung von mycobacterium zur tumorbehandlung
DE59008148D1 (de) Anordnung zur Gewebestimulation.
DE69716896D1 (de) Substituierte benzylamine-derivate und ihre verwendung zur behandlung von depression
DE69734163D1 (de) Kiefernnadelextrakt sowie dessen verwendung
DE59603431D1 (de) Verfahren zur herstellung von organisch modifizierten aerogelen und deren verwendung
DE69118625T2 (de) Papierherstellungsverfahren und Egoutteur zur Verwendung darin
DE69711223T2 (de) Verwendung von cordia dichotoma extrakten
DE50011084D1 (de) Verwendung von azolen zur prävention von strahlen-induziertem hautkrebs
DE69834799D1 (de) Vorrichtung zur Bewegungseinschränkung von Lasten
DE59711240D1 (de) Verwendung von flupirtin zur therapie und prophylaxe von myokardinfarkt, schockniere und schocklunge
DE69110861T2 (de) Mittel zur verbesserung des kollagenmetabolismus und dessen verwendung.
DE29610316U1 (de) Vorrichtung zur Herstellung von Erdbohrungen
DE59712374D1 (de) Verwendung von hcc-1 zur behandlung von thrombozytopenien
DE69302250D1 (de) Verwendung von Isoquinolinon-Derivaten zur Behandlung von Hyperlipoproteinemia
ATE253366T1 (de) Verwendung von 7-apha-methyl-17-alpha-ethynyl- estrane derivaten zur behandlung von atherosclerose
DE29605796U1 (de) Vorrichtung zur Verhinderung des Niederlassens von Lebewesen
DE69907685D1 (de) Verwendung von derivaten von tetrahydropyridinen oder (4-hydroxypiperidin)-butylazolen zur herstellung von präparaten zur schmerzbehandlung
DE29708342U1 (de) Bauelement zur Rekonstruktion von Steinfassaden
DE29622433U1 (de) Vorrichtung zur Fertigung von Möbelstücken

Legal Events

Date Code Title Description
8332 No legal effect for de
8370 Indication related to discontinuation of the patent is to be deleted
8339 Ceased/non-payment of the annual fee